Themis Medicare Limited
Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients (APIs) and formulations used in various therapeutic areas, including anti-tuberculosis, analgesic and anti-inflammatory, analgesic and antispasmodic, analgesics, anesthesia, antacid-antiflatulent, anti-fungal, antibiotic,… Read more
Themis Medicare Limited (THEMISMED) - Net Assets
Latest net assets as of September 2025: ₹3.80 Billion INR
Based on the latest financial reports, Themis Medicare Limited (THEMISMED) has net assets worth ₹3.80 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹5.82 Billion) and total liabilities (₹2.02 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹3.80 Billion |
| % of Total Assets | 65.24% |
| Annual Growth Rate | 10.49% |
| 5-Year Change | 84.25% |
| 10-Year Change | 410.34% |
| Growth Volatility | 19.44 |
Themis Medicare Limited - Net Assets Trend (2006–2025)
This chart illustrates how Themis Medicare Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Themis Medicare Limited (2006–2025)
The table below shows the annual net assets of Themis Medicare Limited from 2006 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹4.03 Billion | +6.60% |
| 2024-03-31 | ₹3.78 Billion | +11.26% |
| 2023-03-31 | ₹3.39 Billion | +18.07% |
| 2022-03-31 | ₹2.87 Billion | +31.57% |
| 2021-03-31 | ₹2.19 Billion | +19.39% |
| 2020-03-31 | ₹1.83 Billion | +15.78% |
| 2019-03-31 | ₹1.58 Billion | -6.39% |
| 2018-03-31 | ₹1.69 Billion | +40.17% |
| 2017-03-31 | ₹1.20 Billion | +52.70% |
| 2016-03-31 | ₹788.89 Million | +33.92% |
| 2015-03-31 | ₹589.08 Million | +4.85% |
| 2014-03-31 | ₹561.85 Million | +4.59% |
| 2013-03-31 | ₹537.17 Million | -7.51% |
| 2012-03-31 | ₹580.79 Million | -36.20% |
| 2011-03-31 | ₹910.26 Million | +9.22% |
| 2010-03-31 | ₹833.43 Million | -9.28% |
| 2009-03-31 | ₹918.65 Million | +8.60% |
| 2008-03-31 | ₹845.93 Million | +22.31% |
| 2007-03-31 | ₹691.60 Million | +14.27% |
| 2006-03-31 | ₹605.21 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Themis Medicare Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 257268900000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹2.57 Billion | 63.90% |
| Common Stock | ₹92.04 Million | 2.29% |
| Other Comprehensive Income | ₹1.01 Billion | 24.98% |
| Other Components | ₹355.66 Million | 8.83% |
| Total Equity | ₹4.03 Billion | 100.00% |
Themis Medicare Limited Competitors by Market Cap
The table below lists competitors of Themis Medicare Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Global Graphics PLC
BR:HYSG
|
$20.42 Million |
|
Black Canyon Ltd
AU:BCA
|
$20.42 Million |
|
Cactus Acquisition Corp 1 Ltd
NASDAQ:CCTS
|
$20.42 Million |
|
Salter Brothers Emerging Companies Ltd
AU:SB2
|
$20.42 Million |
|
Kim Forest Enterprise Co., Ltd.
TW:6645
|
$20.40 Million |
|
P.C.S. Machine Group Holding Public Company Limited
BK:PCSGH
|
$20.40 Million |
|
Israel Canada
TA:ISCN
|
$20.40 Million |
|
United Polyfab Gujarat Limited
NSE:UNITEDPOLY
|
$20.40 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Themis Medicare Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,776,666,000 to 4,026,011,000, a change of 249,345,000 (6.6%).
- Net income of 298,330,000 contributed positively to equity growth.
- Dividend payments of 46,020,000 reduced retained earnings.
- Other comprehensive income decreased equity by 3,994,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹298.33 Million | +7.41% |
| Dividends Paid | ₹46.02 Million | -1.14% |
| Other Comprehensive Income | ₹-3.99 Million | -0.1% |
| Other Changes | ₹1.03 Million | +0.03% |
| Total Change | ₹- | 6.60% |
Book Value vs Market Value Analysis
This analysis compares Themis Medicare Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.72x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 9.91x to 1.72x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-03-31 | ₹7.59 | ₹75.29 | x |
| 2007-03-31 | ₹7.53 | ₹75.29 | x |
| 2008-03-31 | ₹9.21 | ₹75.29 | x |
| 2009-03-31 | ₹9.98 | ₹75.29 | x |
| 2010-03-31 | ₹9.06 | ₹75.29 | x |
| 2011-03-31 | ₹9.89 | ₹75.29 | x |
| 2012-03-31 | ₹6.31 | ₹75.29 | x |
| 2013-03-31 | ₹5.84 | ₹75.29 | x |
| 2014-03-31 | ₹6.11 | ₹75.29 | x |
| 2015-03-31 | ₹6.40 | ₹75.29 | x |
| 2016-03-31 | ₹8.57 | ₹75.29 | x |
| 2017-03-31 | ₹13.09 | ₹75.29 | x |
| 2018-03-31 | ₹18.36 | ₹75.29 | x |
| 2019-03-31 | ₹17.18 | ₹75.29 | x |
| 2020-03-31 | ₹19.89 | ₹75.29 | x |
| 2021-03-31 | ₹23.74 | ₹75.29 | x |
| 2022-03-31 | ₹31.24 | ₹75.29 | x |
| 2023-03-31 | ₹36.82 | ₹75.29 | x |
| 2024-03-31 | ₹40.96 | ₹75.29 | x |
| 2025-03-31 | ₹43.72 | ₹75.29 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Themis Medicare Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.41%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.36%
- • Asset Turnover: 0.69x
- • Equity Multiplier: 1.46x
- Recent ROE (7.41%) is above the historical average (7.21%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 15.38% | 6.00% | 0.77x | 3.34x | ₹37.29 Million |
| 2008 | 21.25% | 7.55% | 0.87x | 3.22x | ₹95.36 Million |
| 2009 | -12.36% | -5.29% | 0.73x | 3.20x | ₹-205.42 Million |
| 2010 | 24.70% | 9.01% | 0.83x | 3.31x | ₹122.51 Million |
| 2011 | 10.97% | 3.99% | 0.85x | 3.23x | ₹8.81 Million |
| 2012 | -58.17% | -21.43% | 0.56x | 4.81x | ₹-395.93 Million |
| 2013 | -8.88% | -2.75% | 0.63x | 5.09x | ₹-101.44 Million |
| 2014 | 4.18% | 1.20% | 0.68x | 5.07x | ₹-32.73 Million |
| 2015 | 8.50% | 2.48% | 0.72x | 4.74x | ₹-8.84 Million |
| 2016 | 24.49% | 8.30% | 0.84x | 3.50x | ₹114.34 Million |
| 2017 | 16.18% | 7.93% | 0.79x | 2.57x | ₹74.44 Million |
| 2018 | 6.69% | 5.39% | 0.69x | 1.81x | ₹-55.95 Million |
| 2019 | -6.79% | -5.85% | 0.59x | 1.99x | ₹-265.51 Million |
| 2020 | 13.54% | 12.29% | 0.58x | 1.91x | ₹64.79 Million |
| 2021 | 16.34% | 15.48% | 0.62x | 1.70x | ₹138.52 Million |
| 2022 | 25.35% | 18.47% | 0.92x | 1.49x | ₹441.32 Million |
| 2023 | 16.76% | 16.06% | 0.69x | 1.51x | ₹229.57 Million |
| 2024 | 11.52% | 11.40% | 0.67x | 1.50x | ₹57.57 Million |
| 2025 | 7.41% | 7.36% | 0.69x | 1.46x | ₹-104.27 Million |
Industry Comparison
This section compares Themis Medicare Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Themis Medicare Limited (THEMISMED) | ₹3.80 Billion | 15.38% | 0.53x | $20.41 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |